drugset / Trial / NCT00004057
Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas
Phase 1
Completed
40 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining paclitaxel and L-778,123 in treating patients who have recurrent or refractory solid tumors or lymphomas.
Timeline
- Start
- 1998-12
- Primary completion
- 2000-12
- Completion
- 2000-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-778,123 | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |